Key points for investors:
- Product leadership & R&D: Cochlear prioritized and protected R&D despite softer sales in FY25, continuing multi-year investment that produced the new Nexa system (world's first "smart" cochlear implant). Management views Nexa as a competitive step-change with near-term benefits (smaller external processor, on‑implant MAP/Smart Sync, easier spares/clinic workflows) and longer‑term upside from new stimulation modes, diagnostics and neural‑health measurement.
- FY25 results and drivers: Group revenue grew ~4% (3% in constant currency). Cochlear implants grew ~9% with system revenue +12%; services declined (~10%) and acoustics were +6% (Osia +30%). Services/upgrades were the main soft spot, with U.S. consumer caution (co‑pay/cost‑of‑living) and COVID-era timing effects on the eligible base cited as drivers.
- FY26 outlook & margin: Guidance A$435–460m (11–17% reported growth; 5–11% growth excluding cloud costs). Management expects >10% unit growth in developed‑market CIs (weighted to H2 as Nexa rolls out, including U.S. FDA timing) and single‑digit growth in services. Net margin target remains ~18% but management expects to be slightly below in FY26 as R&D is maintained and some STI provision is rebuilt.
- Investments & one‑offs: Continued investment in cloud/transformation and ERP replacement (total transformation ~A$250m; ~A$130m to be incurred in FY26–27 and to be reported as a significant item from FY26). Cloud-related spend will be reported post‑tax at ~A$80m for FY26. FY25 included a ~A$50m reduction in the short‑term incentive provision (due to below‑target outcomes).
- Balance sheet & cash flow: Working capital rose ~A$200m, driven by inventory (+A$108m, built ahead of major product launches and safety stocks) and higher receivables; operating cash flow fell ~A$150m. CapEx was ~A$103m, including manufacturing capacity expansions. Chengdu ramp (implant manufacturing) and higher mix of lower‑margin emerging‑market volumes (including China VBP) are near‑term gross‑margin headwinds.
- Market dynamics: Emerging markets strong in volume but skewing to lower tiers (esp. China after volume‑based pricing), creating revenue/margin headwinds. Management remains confident in long‑term market opportunity (penetration <5%) aided by growing evidence linking hearing treatment to cognition and by active DTC/referral programs.
- Risks & execution: Key near‑term risks include services/upgrade demand recovery (consumer sentiment, co‑pays), the pace of Nexa rollout and contracting/pricing, Chengdu gross‑margin ramp, and the timing/visibility of government grants and tenders in emerging markets.
Sign In
Buy CHEOY
